Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris N.V., a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 8,270,500 ordinary shares at $20.00 per share, totaling gross proceeds of approximately $165.4 million. The offering includes a 30-day over-allotment option for an additional 1,240,575 shares. Shares will trade on the Nasdaq under the symbol PHVS starting February 5, 2021. The offering aims to advance Pharvaris's development of oral bradykinin-B2-receptor antagonists for hereditary angioedema and other conditions.